Elevance Health, Inc. (VIE:ELV)
Austria · Delayed Price · Currency is EUR | Market Cap | 74.30B +24.1% |
| Revenue (ttm) | 176.04B +6.3% |
| Net Income | 4.34B -7.4% |
| EPS | 19.67 -3.9% |
| Shares Out | n/a |
| PE Ratio | 17.10 |
| Forward PE | 15.02 |
| Dividend | 5.91 (1.72%) |
| Ex-Dividend Date | Sep 10, 2026 |
| Volume | n/a |
| Open | 344.80 |
| Previous Close | 346.80 |
| Day's Range | 343.10 - 344.80 |
| 52-Week Range | 240.80 - 378.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 14, 2026 |
About Elevance Health
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, a... [Read more]
Financial Performance
In 2025, Elevance Health's revenue was $199.13 billion, an increase of 12.62% compared to the previous year's $176.81 billion. Earnings were $5.66 billion, a decrease of -5.32%.
Financial numbers in USD Financial StatementsNews
Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
INDIANAPOLIS--(BUSINESS WIRE)--Cancer care is often overwhelming, not just medically, but emotionally and logistically. Elevance Health is strengthening its connected cancer care model to enhance supp...
Elevance Health CEO buys $1M in shares
Elevance Health (ELV) CEO Gail Boudreaux purchased 2,725 shares of company stock at an average price of $367.79 per share in a series of purchases valued at about $1M, according…
Elevance Health price target raised to $395 from $364 at Leerink
Leerink raised the firm’s price target on Elevance Health (ELV) to $395 from $364 and keeps a Market Perform rating on the shares. The firm says Q2 results brought forth…
Elevance Health price target raised to $488 from $482 at Bernstein
Bernstein raised the firm’s price target on Elevance Health (ELV) to $488 from $482 and keeps an Outperform rating on the shares. The firm notes that the company’s Q2 earnings…
Elevance Health price target lowered to $424 from $439 at RBC Capital
RBC Capital lowered the firm’s price target on Elevance Health (ELV) to $424 from $439 and keeps a Sector Perform rating on the shares. The outsized 8.5% decline in the…
Elevance Health price target raised to $395 from $370 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Elevance Health (ELV) to $395 from $370 and keeps a Neutral rating on the shares. Shares fell after the company’s Q2 Medical…
Elevance Health price target raised to $455 from $399 at Guggenheim
Guggenheim raised the firm’s price target on Elevance Health (ELV) to $455 from $399 and keeps a Buy rating on the shares after the company reported Q2 operational upside with…
Elevance Health price target raised to $393 from $331 at Baird
Baird raised the firm’s price target on Elevance Health (ELV) to $393 from $331 and keeps a Neutral rating on the shares. The firm updated its model following beat and…
Elevance Health price target lowered to $473 from $492 at Wells Fargo
Wells Fargo analyst Stephen Baxter lowered the firm’s price target on Elevance Health (ELV) to $473 from $492 and keeps an Overweight rating on the shares. Overall, results were modestly…
Elevance Health price target lowered to $457 from $480 at Barclays
Barclays lowered the firm’s price target on Elevance Health (ELV) to $457 from $480 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Elevance Health Earnings Call Transcript: Q2 2026
Second quarter results exceeded expectations, prompting a raise in 2026 EPS guidance to at least $27 and reaffirming confidence in at least 12% EPS growth for 2027. Medicaid remains challenging but manageable, with targeted market exits and prudent margin outlook, while Medicare Advantage, Commercial, and Carelon segments show strong performance and growth potential.
Elevance Health Slides: Q2 2026
Elevance Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 15, 2026.
Elevance Health Earnings release: Q2 2026
Elevance Health released its Q2 2026 earnings on July 15, 2026, summarizing the period's financial results.
Elevance Health Quarterly report: Q2 2026
Elevance Health has published its Q2 2026 quarterly earnings report on July 15, 2026.
Elevance Health down 6% in pre-market at $399.90 after Q2 results
08:17 EDT Elevance Health (ELV) down 6% in pre-market at $399.90 after Q2 results
Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat
Elevance Health reported second quarter net income of $1.45 billion as medical costs fell in some health plans, triggering an improved outlook for the rest of the year.
Elevance Health Raises Earnings Outlook on Higher Sales
The health insurer raised its earnings outlook after logging a higher benefit-expense ratio and sales number in the second quarter.
Elevance raises annual profit forecast on better medical cost management
Elevance Health raised its annual profit forecast after beating second-quarter earnings estimates on Wednesday, as it looks to keep medical costs in check.
Elevance Health raises FY26 operating cash flow view to ‘at least $6B’
Prior view was “at least $5.5B.”
Elevance Health reports Q2 adjusted EPS $7.45, consensus $6.21
Reports Q2 revenue $49.8B, consensus $48.63B. Gail Boudreaux President and Chief Executive Officer: “Our second quarter results exceeded our outlook, supported by disciplined execution and improved op...
Elevance Health raises FY26 adjusted EPS view to ‘at least $27.00’
Prior view was FY26 adjusted EPS “at least $26.75,” consensus $26.91.
Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
INDIANAPOLIS--(BUSINESS WIRE)--Elevance Health, Inc. (NYSE: ELV) reported second quarter 2026 results ahead of expectations. "Our second quarter results exceeded our outlook, supported by disciplined ...
Elevance Health price target raised to $465 from $400 at TD Cowen
TD Cowen raised the firm’s price target on Elevance Health (ELV) to $465 from $400 and keeps a Buy rating on the shares. The firm adjusted targets in the healthcare…
Elevance Health price target raised to $475 from $450 at Truist
Truist raised the firm’s price target on Elevance Health (ELV) to $475 from $450 and keeps a Buy rating on the shares as part of a broader research note previewing…
Eyes On Elevance Health, UnitedHealth For Continued Insurer Rebound
This week's Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies' health insurance businesses and that of their rivals are keeping a handle on risin...